Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 118 results.
User Information
Export Records
  1. 1.   The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
  2. Kendsersky, Nathan M.; Lindsay, Jarrett; Kolb, E. Anders; Smith, Malcolm A.; Teicher, Beverly A.; Erickson, Stephen W.; Earley, Eric J.; Mosse, Yael P.; Martinez, Daniel; Pogoriler, Jennifer; Krytska, Kateryna; Patel, Khushbu; Groff, David; Tsang, Matthew; Ghilu, Samson; Wang, Yifei; Seaman,Steven; Feng,Yang; St Croix,Brad; Gorlick, Richard; Kurmasheva, Raushan; Houghton, Peter J.; Maris, John M.
  3. CLINICAL CANCER RESEARCH. 2021, May 15; 27(10): 2938-2946.
  1. 2.   Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature
  2. Cheng, Cheng; Duan, Hongying; Xu, Kai; Chuang, Gwo-Yu; Corrigan, Angela R; Geng, Hui; O'Dell, Sijy; Ou, Li; Chambers, Michael; Changela, Anita; Chen, Xuejun; Foulds, Kathryn E; Sarfo, Edward K; Jafari, Alexander J; Hill, Kurt R; Kong, Rui; Liu, Kevin; Todd, John P; Tsybovsky,Yaroslav; Verardi, Raffaello; Wang, Shuishu; Wang, Yiran; Wu, Winston; Zhou, Tongqing; Arnold, Frank J; Doria-Rose, Nicole A; Koup, Richard A; McDermott, Adrian B; Scorpio, Diana G; Worobey, Michael; Shapiro, Lawrence; Mascola, John R; Kwong, Peter D
  3. Cell reports. 2020, Aug 04; 32(5): 107981.
  1. 3.   Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens
  2. Ueda, George; Antanasijevic, Aleksandar; Fallas, Jorge A; Sheffler, William; Copps, Jeffrey; Ellis, Daniel; Hutchinson, Geoffrey B; Moyer, Adam; Yasmeen, Anila; Tsybovsky,Yaroslav; Park, Young-Jun; Bick, Matthew J; Sankaran, Banumathi; Gillespie, Rebecca A; Brouwer, Philip Jm; Zwart, Peter H; Veesler, David; Kanekiyo, Masaru; Graham, Barney S; Sanders, Rogier W; Moore, John P; Klasse, Per Johan; Ward, Andrew B; King, Neil P; Baker, David
  3. eLife. 2020, Aug 04; 9: pii: 9:e57659.
  1. 4.   A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules
  2. Gatti-Mays, Margaret E.; Strauss, Julius; Donahue, Renee N.; Palena, Claudia; Del Rivero, Jaydira; Redman, Jason M.; Madan, Ravi A.; Marte, Jennifer L.; Cordes, Lisa M.; Lamping, Elizabeth; Orpia,Alanvin; Burmeister, Andrea; Wagner, Eva; Navarro, Cesar Pico; Heery, Christopher R.; Schlom, Jeffrey; Gulley, James L.
  3. CLINICAL CANCER RESEARCH. 2019, Aug 15; 25(16): 4933-4944.
  1. 5.   CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
  2. Majzner, Robbie G.; Theruvath, Johanna L.; Nellan, Anandani; Heitzeneder, Sabine; Cui, Yongzhi; Mount, Christopher W.; Rietberg, Skyler P.; Linde, Miles H.; Xu, Peng; Rota, Christopher; Sotillo, Elena; Labanieh, Louai; Lee, Daniel W.; Orentas, Rimas J.; Dimitrov, Dimiter S.; Zhu, Zhongyu; St Croix,Brad; Delaidelli, Alberto; Sekunova, Alla; Bonvini, Ezio; Mitra, Siddhartha S.; Quezado, Martha M.; Majeti, Ravindra; Monje, Michelle; Sorensen, Poul H. B.; Maris, John M.; Mackall, Crystal L.
  3. CLINICAL CANCER RESEARCH. 2019, APR 15; 25(8): 2560-2574.
  1. 6.   Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF beta, in Advanced Solid Tumors
  2. Strauss, Julius; Heery, Christopher R.; Schlom, Jeffrey; Madan, Ravi A.; Cao, Liang; Kang, Zhigang; Lamping, Elizabeth; Marte, Jennifer L.; Donahue, Renee N.; Grenga, Italia; Cordes, Lisa; Christensen, Olaf; Mahnke, Lisa; Helwig, Christoph; Gulley, James L.
  3. Clinical Cancer Research. 2018, Mar 15; 24(6): 1287-1295.
  1. 7.   Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use
  2. Williams, P. M.; Lively, T. G.; Jessup, J. M.; Conley, B. A.
  3. Clinical Cancer Research. 2012, Mar; 18(6): 1531-1539.
  1. 8.   STATE-OF-THE-ART THERAPEUTIC MEDICAL COUNTERMEASURES FOR VIRAL THREAT AGENTS
  2. Sampath, A.; Metz, M.; Stundick, M.; Larsen, J. C.
  3. Biosecurity and Bioterrorism-Biodefense Strategy Practice and Science. 2011, Dec; 9(4): 351-360.
  1. 9.   Engineered Single Human CD4 Domains as Potent HIV-1 Inhibitors and Components of Vaccine Immunogens
  2. Chen, W. Z.; Feng, Y.; Gong, R.; Zhu, Z. Y.; Wang, Y. P.; Zhao, Q.; Dimitrov, D. S.
  3. Journal of Virology. 2011, Sep; 85(18): 9395-9405.
  1. 10.   Ex vivo functional responses to HLA-G differ between blood and decidual NK cells
  2. Apps, R.; Sharkey, A.; Gardner, L.; Male, V.; Kennedy, P.; Masters, L.; Farrell, L.; Jones, D.; Thomas, R.; Moffett, A.
  3. Molecular Human Reproduction. 2011, Sep; 17(9): 577-586.
  1. 11.   Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102
  2. Buchanan, I. M.; Scott, T.; Tandle, A. T.; Burgan, W. E.; Burgess, T. L.; Tofilon, P. J.; Camphausen, K.
  3. Journal of Cellular and Molecular Medicine. 2011, Sep; 15(9): 1999-2006.
  1. 12.   Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development
  2. Yuan, T. T.; Li, J. J.; Zhang, Y.; Wang, Y. P.; Streaker, E.; Dimitrov, D. S.; Zhang, M. Y.
  3. Vaccine. 2011, Sep; 29(40): 6903-6910.
  1. 13.   HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
  2. Zielinski, R.; Lyakhov, I.; Hassan, M.; Kuban, M.; Shafer-Weaver, K.; Gandjbakhche, A.; Capala, J.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5071-5081.
  1. 14.   Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
  2. Burton, D. R.; Hessell, A. J.; Keele, B. F.; Klasse, P. J.; Ketas, T. A.; Moldt, B.; Dunlop, D. C.; Poignard, P.; Doyle, L. A.; Cavacini, L.; Veazey, R. S.; Moore, J. P.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2011, Jul; 108(27): 11181-11186.
  1. 15.   Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals
  2. Bhattacharyya, S.; Dixit, M.
  3. Dalton Transactions. 2011, Jun 21; 40(23): 6112-6128.
  1. 16.   mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
  2. Jiang, Q.; Weiss, J. M.; Back, T.; Chan, T.; Ortaldo, J. R.; Guichard, S.; Wiltrout, R. H.
  3. Cancer Research. 2011, Jun; 71(12): 4074-4084.
  1. 17.   Conformational and Structural Features of HIV-1 gp120 Underlying the Dual Receptor Antagonism by Cross-Reactive Neutralizing Antibody m18
  2. Gift, S. K.; Zentner, I. J.; Schon, A.; McFadden, K.; Umashankara, M.; Rajagopal, S.; Contarino, M.; Duffy, C.; Courter, J. R.; Zhang, M. Y.; Gershoni, J. M.; Cocklin, S.; Dimitrov, D. S.; Smith, A. B.; Freire, E.; Chaiken, I. M.
  3. Biochemistry. 2011, Apr; 50(14): 2756-2768.
  1. 18.   Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L)
  2. Mayeenuddin, L. H.; Yu, Y.; Kang, Z.; Helman, L. J.; Cao, L.
  3. Oncogene. 2010, Dec; 29(48): 6367-6377.
  1. 19.   The Antiretroviral Lectin Cyanovirin-N Targets Well-Known and Novel Targets on the Surface of Entamoeba histolytica Trophozoites
  2. Carpentieri, A.; Ratner, D. M.; Ghosh, S. K.; Banerjee, S.; Bushkin, G. G.; Cui, J. K.; Lubrano, M.; Steffen, M.; Costello, C. E.; O'Keefe, B.; Robbins, P. W.; Samuelson, J.
  3. Eukaryotic Cell. 2010, Nov; 9(11): 1661-1668.
  1. 20.   Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
  2. Shusterman, S.; London, W. B.; Gillies, S. D.; Hank, J. A.; Voss, S. D.; Seeger, R. C.; Reynolds, C. P.; Kimball, J.; Albertini, M. R.; Wagner, B.; Gan, J.; Eickhoff, J.; DeSantes, K. B.; Cohn, S. L.; Hecht, T.; Gadbaw, B.; Reisfeld, R. A.; Maris, J. M.; Sondel, P. M.
  3. Journal of Clinical Oncology. 2010, Nov; 28(33): 4969-4975.
  1. 21.   Structural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41
  2. Gustchina, E.; Li, M.; Louis, J. M.; Anderson, D. E.; Lloyd, J.; Frisch, C.; Bewley, C. A.; Gustchina, A.; Wlodawer, A.; Clore, G. M.
  3. Plos Pathogens. 2010, Nov; 6(11): 19.
  1. 22.   Emergence of Simian Immunodeficiency Virus-Specific Cytotoxic CD4(+) T Cells and Increased Humoral Responses Correlate with Control of Rebounding Viremia in CD8-Depleted Macaques Infected with Rev-Independent Live-Attenuated Simian Immunodeficiency Virus
  2. von Gegerfelt, A.; Valentin, A.; Alicea, C.; Van Rompay, K. K. A.; Marthas, M. L.; Montefiori, D. C.; Pavlakis, G. N.; Felber, B. K.
  3. Journal of Immunology. 2010, Sep 15; 185(6): 3348-3358.
  1. 23.   In Vivo Binding and Retention of CD4-Specific DARPin 57.2 in Macaques
  2. Pugach, P.; Krarup, A.; Gettie, A.; Kuroda, M.; Blanchard, J.; Piatak, M.; Lifson, J. D.; Trkola, A.; Robbiani, M.
  3. Plos One. 2010, Aug; 5(8): 9.
  1. 24.   Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1
  2. Zhang, M. Y.; Borges, A. R.; Ptak, R. G.; Wang, Y. P.; Dimitrov, A. S.; Alam, S. M.; Wieczorek, L.; Bouma, P.; Fouts, T.; Jiang, S. B.; Polonis, V. R.; Haynes, B. F.; Quinnan, G. V.; Montefiori, D. C.; Dimitrov, D. S.
  3. Mabs. 2010, May-Jun; 2(3): 266-274.
  1. 25.   Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies
  2. Xiao, X. D.; Chen, W. Z.; Feng, Y.; Dimitrov, D. S.
  3. Viruses-Basel. 2009, Dec; 1(3): 802-817.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel